Stephanie L. Graff, MD, FACP

Articles

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

April 11th 2024

Drs Graff, Mahtani, McCann, and Rugo share moments that sparked their interest in oncology and setbacks they overcame when building their careers.

Dr Graff on the Trajectory of Her Career in Breast Cancer

March 11th 2024

Stephanie L. Graff, MD, discusses the trajectory of her career growth in breast oncology and explains how different factors can play a role in an oncologist’s career path.

Dr Graff on the Relation Between ctDNA Positivity and Disease Recurrence in HR+/HER2– Breast Cancer

December 7th 2023

Stephanie L. Graff, MD, discusses findings from a pilot study exploring the association between disease recurrence and circulating tumor DNA positivity in patients with hormone receptor–positive, HER2-negative, node-positive, high-risk, early breast cancer who have received adjuvant treatment of abemaciclib and endocrine therapy.

Dr Graff on the Impact of Endocrine Therapy Interruption on Conception in Breast Cancer Survivors

September 19th 2023

Stephanie L. Graff, MD, discusses the advantages of interrupting endocrine therapy in premenopausal patients with endocrine-responsive breast cancer who are seeking to conceive, based on findings from the phase 3 POSITIVE trial.

What is on the Horizon for Adjuvant Therapy in Early-Stage Breast Cancer?

August 17th 2023

Expert medical oncologists take a step into the future and discuss developments within the adjuvant setting of early-stage breast cancer they are most excited about.

Managing Toxicities and Adverse Events of CDK 4/6 Inhibitors

August 10th 2023

Stephanie Graff, MD, and Rachel Layman, MD, review common toxicities and adverse effects to watch out for with endocrine therapy and CDK4/6 inhibitors, and how to manage these.

Impact of Trial Data on Clinical Practice

August 10th 2023

Expert medical oncologists talk about the impact of NATALEE trial data on their medical practice.

Key Findings from the NATALEE Trial

August 3rd 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the NATALEE trial, which evaluated adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer.

Risk of Recurrence

August 3rd 2023

Stephanie Graff, MD, describes her impression of the case and discusses the risk for recurrence in this particular patient.

Clinical Case 2: High-Risk Early-Stage HR+ Breast Cancer

July 27th 2023

Rachel Layman, MD, presents a clinical case of a patient who is diagnosed with HR+ early-stage breast cancer.

Selecting Endocrine Therapy in BRCA1/BRCA2+ Breast Cancer

July 27th 2023

Experts in breast oncology discuss how they select endocrine therapy in BRCA1/BRCA2+ breast cancer.

Implementing Trial Data to Our Practice

July 20th 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss how they would apply the results of the monarchE trial to clinical case scenarios.

Dosing CDK 4/6 Inhibitors

July 20th 2023

Rachel Layman, MD, summarizes how to dose CDK4/6 inhibitors in different clinical settings.

Age-Dependent Results With CDK 4/6 Inhibitors

July 13th 2023

Experts in breast oncology review age-dependent outcomes with CDK 4/6 inhibitors.

Individualizing Care with CDK 4/6 Inhibitors

July 13th 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss how to individualize care with CDK4/6 inhibitors in patients with high-risk early breast cancer.

Key Findings from the monarchE Trial

July 6th 2023

Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the monarchE trial, which evaluated abemaciclib plus endocrine therapy for HR+, HER2 negative, node positive, high-risk early breast cancer.

Endocrine Therapy for Early-Stage Breast Cancer

July 6th 2023

Expert medical oncologists provide an overview of current endocrine therapy approved for early-stage breast cancer.

Risk Factors and the Treatment Plan

June 29th 2023

Rachel Layman, MD, describes her impression of the case and discusses risk assessment and a treatment plan for the patient.

Clinical Case 1: High-Risk Early-Stage HR+ Breast Cancer

June 29th 2023

Stephanie Graff, MD, presents a clinical case of a patient who is diagnosed with HR+ early-stage breast cancer.

Dr Graff on the Investigation of Datopotamab Deruxtecan in HR+ Breast Cancer and TNBC

May 4th 2023

Stephanie L. Graff, MD, discusses current and planned investigations of the emerging antibody-drug conjugate datopotamab deruxtecan in patients with metastatic hormone receptor–positive breast cancer and triple-negative breast cancer.